TriSalus Life Sciences - TLSI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 174.73%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.55
▲ +0.24 (5.57%)

This chart shows the closing price for TLSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TriSalus Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLSI

Analyst Price Target is $12.50
▲ +174.73% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for TriSalus Life Sciences in the last 3 months. The average price target is $12.50, with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 174.73% upside from the last price of $4.55.

This chart shows the closing price for TLSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in TriSalus Life Sciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/16/2024OppenheimerInitiated CoverageOutperform$10.00
6/27/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/30/2024Canaccord Genuity GroupInitiated CoverageBuy$12.00
5/30/2024Canaccord Genuity GroupInitiated CoverageBuy$12.00
5/10/2024JonestradingInitiated CoverageBuy$16.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

1.01 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/6/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2024

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
TriSalus Life Sciences logo
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Read More

Today's Range

Now: $4.55
Low: $4.28
High: $4.82

50 Day Range

MA: $5.15
Low: $4.01
High: $5.89

52 Week Range

Now: $4.55
Low: $3.32
High: $10.42

Volume

16,537 shs

Average Volume

40,550 shs

Market Capitalization

$123.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of TriSalus Life Sciences?

The following Wall Street analysts have issued research reports on TriSalus Life Sciences in the last twelve months: Canaccord Genuity Group Inc., Jonestrading, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TLSI.

What is the current price target for TriSalus Life Sciences?

4 Wall Street analysts have set twelve-month price targets for TriSalus Life Sciences in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 174.7%. Jonestrading has the highest price target set, predicting TLSI will reach $16.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $10.00 for TriSalus Life Sciences in the next year.
View the latest price targets for TLSI.

What is the current consensus analyst rating for TriSalus Life Sciences?

TriSalus Life Sciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TLSI will outperform the market and that investors should add to their positions of TriSalus Life Sciences.
View the latest ratings for TLSI.

What other companies compete with TriSalus Life Sciences?

How do I contact TriSalus Life Sciences' investor relations team?

TriSalus Life Sciences' physical mailing address is 6272 West 91st Avenue, Westminster, CO 80031, United States. The company's listed phone number is 888-321-5212 and its investor relations email address is [email protected]. The official website for TriSalus Life Sciences is trisaluslifesci.com. Learn More about contacing TriSalus Life Sciences investor relations.